Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme…

• Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
• Further evidence for Intravacc's versatile multi-disease OMV platform
• Data are published in peer reviewed journal Vaccine

Intravacc announces positive pre-clinical data for its SARS-CoV-2 nose spray vaccine Bilthoven, the Netherlands, 7 April 2021 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive pre-clinical results…

• Intranasal administration of OMV-Spike protected against challenge with SARS-CoV-2
• Intranasal vaccine administration has significant advantages over injectables
• OMV technology is a powerful vaccine platform for future pandemics

Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer Bilthoven, the Netherlands, 24 March 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the appointment of Nathalie Laarakker as Chief Financial Officer and member…